NeuroPrecision-Engine

NeuroPrecision-Engine is a biotechnology research company based in Sursee, Switzerland, that operates an in silico AI platform dedicated to central nervous system (CNS) drug discovery. Founded in 2026, the company focuses on overcoming the blood-brain barrier (BBB), which is identified as the primary reason for the high failure rate of CNS drugs. Their technology utilizes a 65-gate, GPU-accelerated pipeline that integrates physics-based scoring and cross-species translation models. By moving beyond traditional LLM-based approaches, the platform provides real-number molecular simulations to evaluate target binding, safety, and BBB permeability from the initial stages of development.

Designed to serve pharmaceutical companies, biotech firms, academic groups, and contract research organizations, the platform aims to accelerate the transition of candidates from target identification to clinical readiness. By filtering molecules in silico within days, the company seeks to reduce development timelines and failure rates during early-stage discovery. The startup is a member of the NVIDIA for Startups Inception program, providing access to advanced computational resources and tools like BioNeMo NIMs, and it actively engages in scientific forums to present its framework for closed-loop drug discovery.